10Q PRO AND CONTRA
FROM LAST NIGHT HERE ON BOARD, SPECIALLY LEWIS (LEWOGGE??) HAD VERY SHARP MINDS AND HELPED US, HERE WE GO:
The Bad:
-The only area of concern I saw was the pending lawsuit over $165,000 I don't think any of us knew about until now. Since this is such a small amount in the grand scheme of AMBS' financing, and they already paid off $10,000, I don't see this being much of a speed bump at all, regardless of how the lawsuit goes. Hopefully all those who continue to hold large amounts of shares agree. This was merely some behind the scenes activity they were legally obligated to report.
The Good
+The international courts upheld AMBS' status as the sole owner of MANF rights against a very recent dispute in Europe less than 2 weeks ago. This news is HUGE for us long term holders. If AMBS were to lose their sole ownership rights of this patent then there would be shockwaves felt far and wide. I don't blame management for keeping this off the radar from us investors, and its reassuring to learn that MANF is still completely owned by AMBS and has now expanded its target market to include not just Parkinsons, but several other, (and in one case completely) underdeveloped markets. AMBS is turning heads in the international market, and from the looks of it a few companies are getting jealous. AMBS dodged a major bullet here, and this court's decision will likely serve as a precedent for the future when AMBS takes off and greed really kicks in.
+The high net investors continuing agreements to provide funding for MANF show that they believe the stock value will rise to what us speculators are hoping... .1 and higher! The bashers are going to claim this is dilution or scamming, but that is most certainly not the case. This is a drug with extreme potential and AMBS has been raising the necessary funding according to the plan they laid out weeks ago. These debtors wouldn't risk their assets if they didn't think they were getting a good deal. With a lot of conversionary notes valued at .06 and a maturation date just weeks away (12/6/2012) the short term looks promising. Recent investors, who are beginning to throw a lot more money AMBS' way are agreeing to .1$ and .2$ PPS which is GOOD. All indications show that investors holding long, like myself, are going to be the big money makers. AMBS is receiving support they have never seen before. Just look at the 10Q and look at where we are at now. Ideally we would have loved to see the recent developments and funding documented in this 10Q, but unfortunately we just missed that. Still, nothing has changed and AMBS is on path to potentially become one of the best picks of the year. The panic sell off from the rise in A/S got a lot of the manipulative trading groups out of the equation, and provided a solid entry point for new honest traders.
+outstanding shares with convertables ( for 0,05 0,1! und 0,2!!) 224million. date 16.11.2012
+no dilution,
+hold all steppromisses.
+auth. shares not for dilution,for protect amarantus biosciencesfrom buyout,
+marketcap 10 million $ for a possible blockbuster
with 5 billion $ income/year.(tag* had 100 millionen $ marketcap 2 weeks ago).
+amarantus biosciences transparency.
+greatcomunikation
+professionells on bord (cofounderr von amgen, bayer..)
+did get allready before grant fund from michael j fox grant next maybe in december.
+klinik testresultate positiv and very good (says amgen cofounder and ambs ceo)
+share at 0,048 now.
